Diabetes and cardiovascular disease: The role of glycemic control
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Over the past decade, clinical practice guidelines have lowered their glycemic targets for people with type 2 diabetes. However, recent randomized controlled trials (ACCORD, ADVANCE, and VADT) demonstrate that intensive glycemic targets do not reduce cardiovascular risk among higher-risk individuals over a period of 3.5 to 5 years. Thus, targeting a hemoglobin A1c below 6% among high-risk patients should not be recommended. However, the 10-year post-trial monitoring of the UKPDS demonstrated cardiovascular benefit of intensive glycemic control among those with newly diagnosed type 2 diabetes over a median follow-up of 17 years. This raises the possibility that cardiovascular benefits of glycemic control require many years to manifest and early intervention may carry greater benefit. Therefore, these recent trials continue to support the recommended hemoglobin A1c target of below 7% to reduce microvascular complications in type 2 diabetes and perhaps macrovascular complications in those with newly diagnosed diabetes.
- Deedwania P, Kosibrorod M, Barrett E, et al.: Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008, 117:1610–1619. CrossRef
- Capes SE, Hung D, Malmberg K, Gerstein HC: Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic review. Lancet 2000, 355:773–778. CrossRef
- Gerstein HC: Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med 1997, 1:87–88. CrossRef
- Punthakee Z, Werstuck GH, Gerstein HC: Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007, 8:145–153. CrossRef
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.
- Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med 2005, 353:2643–2653. CrossRef
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.
- Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. The ACCORD Study Group [no authors listed]. Am J Cardiol 2007, 99(Suppl):21i–33i.
- Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545–2559.
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560–2572.
- Patel A, MacMahon S, Calmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. ADVANCE Collaborative Group. Lancet 2007, 370:829–840. CrossRef
- Chalmers J: ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) Trial Results. Presented at the 44th European Association for the Study of Diabetes Annual Meeting. Rome, Italy; September 7–11, 2008.
- Duckworth WC, Moritz TE: Glycemic Control and Cardiovascular Outcomes — the VA Diabetes Trial (Symposium). Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA; June 6–10, 2008.
- Abraria C, Duckworth WC, Del Prato S: VA Diabetes Trial Results. Presented at the 44th European Association for the Study of Diabetes Annual Meeting. Rome, Italy; September 7–11, 2008.
- Holman RR, Sanjoy KP, Bethel A, et al.: 10-Year follow-up of intensive glycemic control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589. Available at http://content.nejm.org/cgi/content/abstract/359/15/1577. Accessed October 16, 2008. CrossRef
- Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630–2633. CrossRef
- Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393. CrossRef
- Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591. CrossRef
- Diabetes and cardiovascular disease: The role of glycemic control
Current Diabetes Reports
Volume 9, Issue 1 , pp 65-72
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links